Rare
lephants
Screener
Toggle theme
Amneal Pharmaceuticals, Inc.
AMRX
·
Healthcare, Drug Manufacturers - General
Analysis
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
Total Cash from Operations:
$340.0M
Line Item
Value
% of Total
Capital Expenditures
$70.1M
20.6%
Other Investing
$42.2M
12.4%
Other Financing
$0
0.0%
Other
$33.2M
9.8%
Net Cash Flow
$194.5M
57.2%
Download CSV
